Canaccord raised the firm’s price target on Repligen (RGEN) to $165 from $150 and keeps a Hold rating on the shares. The firm raised estimates given the 3Q25 revenue beat and relatively improving biopharma outlook as the company reported 3Q25 results that were ahead of estimates while the company achieved revenue growth across all franchises led by Process Analytics.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen price target raised to $175 from $160 at Barclays
- Repligen Corporation Reports Strong Q3 2025 Results
- Repligen’s Strong Performance and Strategic Growth Initiatives Earn ‘Buy’ Rating
- Repligen’s Strong Q3 Performance and Upward Revenue Guidance Justify Buy Rating
- Repligen sees FY25 adjusted EPS $1.65-$1.68, consensus $1.69